APOC1 Antikörper (HRP)
Kurzübersicht für APOC1 Antikörper (HRP) (ABIN7449300)
Target
Alle APOC1 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Verwendungszweck
- Goat anti-Human Apo CI [H07] Antibody HRP Conjugated
-
Immunogen
- Human Apolipoprotein CI
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
WB: 1:1,000 - 1:4,000
ELISA: 1:1,000 - 1:4,000
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1 mg/mL
-
Buffer
- 50 mM PBS, 0.1 M NaCl, and 0.01 % Thiomersal, pH 7.4
-
Konservierungsmittel
- Thimerosal (Merthiolate)
-
Vorsichtsmaßnahmen
- This product contains Thimerosal (Merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Haltbarkeit
- 12 months
-
-
- APOC1 (Apolipoprotein C-I (APOC1))
-
Andere Bezeichnung
- ApoCI
-
Hintergrund
- Background: ApoCI contains 57 amino acid residues and the m.w. is 6.6 kDa (Jackson et al., 1974). ApoCI has been found to activate LCAT (Liu and Subbaiah 1993). Apo CI is an inhibitor of lipoprotein binding to the LDL receptor, LDL receptor-related protein, and VLDL receptor. Apo CI is also an inhibitor of the plasma cholesteryl ester transfer protein and of fatty acid uptake into tissues (Shachter, 2001). This inhibition role can potentially regulate several lipase enzymes. (Poensgen, 1990, Conde-Knape et al., 2002, Berbee et al., 2005)
-
Gen-ID
- 341
-
NCBI Accession
- NP_001636
-
UniProt
- P02654
-
Pathways
- Apoptose
Target
-